Abstract: Methods of stimulating a hydrocarbon well are disclosed herein. The hydrocarbon well includes a wellbore that extends within a subterranean formation and a tubular that extends within the wellbore and defines a tubular conduit. The methods include retaining a sealing structure within the tubular conduit and, during the retaining, stimulating a zone of the subterranean formation. Subsequent to the stimulating, the methods include fluidly isolating the zone of the subterranean formation from the uphole region by at least partially sealing the plurality of perforations. Subsequent to the fluidly isolating, the methods include moving the sealing structure in a downhole direction within the tubular conduit. The methods also include repeating the retaining, the stimulating, the fluidly isolating, and the moving a plurality of times to stimulate a plurality of corresponding zones of the subterranean formation.

Abstract: Methods of stimulating a hydrocarbon well are disclosed herein. The hydrocarbon well includes a wellbore that extends within a subterranean formation and a tubular that extends within the wellbore and defines a tubular conduit. The methods include retaining a sealing structure within the tubular conduit and, during the retaining, stimulating a zone of the subterranean formation. Subsequent to the stimulating, the methods include fluidly isolating the zone of the subterranean formation from the uphole region by at least partially sealing the plurality of perforations. Subsequent to the fluidly isolating, the methods include moving the sealing structure in a downhole direction within the tubular conduit. The methods also include repeating the retaining, the stimulating, the fluidly isolating, and the moving a plurality of times to stimulate a plurality of corresponding zones of the subterranean formation.

Abstract: Methods of stimulating a hydrocarbon well are disclosed herein. The hydrocarbon well includes a wellbore that extends within a subterranean formation and a tubular that extends within the wellbore and defines a tubular conduit. The methods include retaining a sealing structure within the tubular conduit and, during the retaining, stimulating a zone of the subterranean formation. Subsequent to the stimulating, the methods include fluidly isolating the zone of the subterranean formation from the uphole region by at least partially sealing the plurality of perforations. Subsequent to the fluidly isolating, the methods include moving the sealing structure in a downhole direction within the tubular conduit. The methods also include repeating the retaining, the stimulating, the fluidly isolating, and the moving a plurality of times to stimulate a plurality of corresponding zones of the subterranean formation.

Abstract: Methods of stimulating a hydrocarbon well are disclosed herein. The hydrocarbon well includes a wellbore that extends within a subterranean formation and a tubular that extends within the wellbore and defines a tubular conduit. The methods include retaining a sealing structure within the tubular conduit and, during the retaining, stimulating a zone of the subterranean formation. Subsequent to the stimulating, the methods include fluidly isolating the zone of the subterranean formation from the uphole region by at least partially sealing the plurality of perforations. Subsequent to the fluidly isolating, the methods include moving the sealing structure in a downhole direction within the tubular conduit. The methods also include repeating the retaining, the stimulating, the fluidly isolating, and the moving a plurality of times to stimulate a plurality of corresponding zones of the subterranean formation.

Abstract: Potent opioid receptor antagonists of formula (I) and their use as pharmacotherapies for treating depression, anxiety, schizophrenia, eating disorders, and addiction to cocaine, methamphetamine, nicotine, alcohol, and opiates are disclosed. More specifically, the disclosure provides potent and selective kappa opioid receptor antagonist compounds, pharmaceutical compositions of those compounds and uses of those compounds to ameliorate or treat addictions, eating disorders, etc.

Abstract: Potent opioid receptor antagonists of formula (I) and their use as pharmacotherapies for treating depression, anxiety, schizophrenia, eating disorders, and addiction to cocaine, methamphetamine, nicotine, alcohol, and opiates are disclosed. More specifically, the disclosure provides potent and selective kappa opioid receptor antagonist compounds, pharmaceutical compositions of those compounds and uses of those compounds to ameliorate or treat addictions, eating disorders, etc.

Abstract: Provided are opioid receptor antagonists represented by the formula (I): where R, Y3, R1, R2, R3, R4 and R5 are as defined herein.

Abstract: This invention relates generally to the discovery of pyrazole compounds selective for the neurotensin receptor 2 (NTR2) and uses thereof.

Abstract: Provided are compounds represented by the formula: where R, Y3, R1, R2, R3, R4, R6, G, R7, E1, E2, A, B, W, X, Y and Z are as defined herein.

Abstract: Provided are opioid receptor antagonists represented by the formula (I): where R, Y3, R1, R2, R3, R4 and R5 are as defined herein.

Abstract: Provided are opioid receptor antagonists represented by the formula (I) where R, Y3, R1, R2, R3, R4 and R5 are as defined herein.

Abstract: An implantable screw system for maintaining horizontal and/or vertical space during bone grafting procedures is provided, the screw comprising: a contoured head having a region adapted to support soft tissue and permit bone growth; a threaded shaft and a tip adapted to penetrate bone tissue; and where one screw contains a threaded chamber for engaging a second screw for additional space maintenance; wherein the screw(s) comprises cortical bone material. Methods of implanting one or more screws during bone grating procedures are disclosed.

Abstract: Provided are compounds represented by the formula: where R, Y3, R1, R2, R3, R4, R6, G, R7, E1, E2, A, B, W, X, Y and Z are as defined herein.

Abstract: Kappa opioid recep-tor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor, such as heroin or cocaine addictions.

Abstract: Provided are opioid receptor antagonists represented by the formula (I) where R, Y3, R1, R2, R3, R4 and R5 are as defined herein.

Abstract: Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions.

Abstract: Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions.

Abstract: Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions.

Abstract: Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions.

Abstract: Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions.